These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 39129317)

  • 1. Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308.
    Nouruzi S; Johnson F; Kumar S; Sivak O; Tabrizian N; Koistinaho M; Muona A; Zoubeidi A
    Oncol Rep; 2024 Oct; 52(4):. PubMed ID: 39129317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer.
    Yoshida S; Kajiwara D; Seki M; Tayama M; Tanaka Y; Mizutani H; Fujita R; Yamamura K; Okajima S; Asai M; Minamiguchi K
    Mol Oncol; 2024 Aug; 18(8):1980-2000. PubMed ID: 38600681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
    Leung JK; Tam T; Wang J; Sadar MD
    Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
    Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
    Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C
    Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression.
    Zhang M; Sun Y; Huang CP; Luo J; Zhang L; Meng J; Liang C; Chang C
    Cell Death Dis; 2021 Sep; 12(10):855. PubMed ID: 34545067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
    Wen S; He Y; Wang L; Zhang J; Quan C; Niu Y; Huang H
    Oncogene; 2020 Oct; 39(42):6556-6571. PubMed ID: 32917955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells.
    Sarwar M; Semenas J; Miftakhova R; Simoulis A; Robinson B; Gjörloff Wingren A; Mongan NP; Heery DM; Johnsson H; Abrahamsson PA; Dizeyi N; Luo J; Persson JL
    Oncotarget; 2016 Sep; 7(39):63065-63081. PubMed ID: 27588408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
    Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
    Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.
    Asangani IA; Wilder-Romans K; Dommeti VL; Krishnamurthy PM; Apel IJ; Escara-Wilke J; Plymate SR; Navone NM; Wang S; Feng FY; Chinnaiyan AM
    Mol Cancer Res; 2016 Apr; 14(4):324-31. PubMed ID: 26792867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
    Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
    EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
    Poutiainen PK; Huhtala T; Jääskeläinen T; Petsalo A; Küblbeck J; Kaikkonen S; Palvimo JJ; Raunio H; Närvänen A; Peräkylä M; Juvonen RO; Honkakoski P; Laatikainen R; Pulkkinen JT
    Mol Cell Endocrinol; 2014 Apr; 387(1-2):8-18. PubMed ID: 24565895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator-activated receptor promotes enzalutamide resistance in prostate cancer.
    Shiota M; Ushijima M; Tsukahara S; Nagakawa S; Okada T; Tanegashima T; Kobayashi S; Matsumoto T; Eto M
    Free Radic Biol Med; 2024 Aug; 221():81-88. PubMed ID: 38762061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
    Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
    Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
    Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells.
    Gupta S; Pungsrinont T; Ženata O; Neubert L; Vrzal R; Baniahmad A
    Horm Cancer; 2020 Aug; 11(3-4):182-190. PubMed ID: 32562083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel biphenyl derivatives as androgen receptor degraders for the treatment of enzalutamide-resistant prostate cancer.
    Zhang W; Fan Y; Zhang Y; Feng Y; Luo Y; Zhou X; Chen Z; Wang C; Lu T; Tang F; Chen Y; Li H; Jiao Y
    Bioorg Chem; 2024 Jul; 148():107433. PubMed ID: 38754311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.